dose-ranging study


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

dose-ranging study

An investigation of different selected drug dosages to determine if any is better tolerated or more effective than the others.
See also: study
Mentioned in ?
References in periodicals archive ?
This dose-ranging study is an ongoing 88-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled multicenter study designed to evaluate the safety and efficacy of upadacitinib in adult patients with moderate to severe atopic dermatitis not adequately controlled by topical treatments, or for whom topical treatments were not medically advisable.
While the safety analysis showed no significant differences from placebo, there were two cases of cardiac disorders - one angina pectoris and one coronary artery disease - in the intravenous dose-ranging study and two cases listed as "cardiac disorders" in the regimen-finding study.
A second, dose-ranging study included 533 obese subjects who were randomized to placebo or taranabant in daily doses of 0.
In this dose-ranging study, AVE5026 was administered for up to 10 days for primary prevention of VTE in patients undergoing elective total knee replacement surgery.
Research: In a randomized, double-blind, placebo-controlled, dose-ranging study, 362 women between 18 and 65 years of age who had been diagnosed with IBS (per Rome II criteria) received placebo or freeze-dried, encapsulated Bifantis once daily for four weeks.
The effect of drospirenone and estradiol on blood pressure was assessed in a dose-ranging study with 750 women.
The trial will be a randomized, placebo-controlled, double blind, parallel-group dose-ranging study in obese Japanese patients with related diseases.
In a multicenter, double-blind, randomized, dose-ranging study sponsored in part by Noven Pharmaceuticals Inc.
Recently reported results from Nastech's Phase I-B dose-ranging study indicated that a single dose of PYY Nasal Spray reduced average calorie intake for each meal, reduced appetite, and was well tolerated; with side effects that were generally mild and all resolved without treatment.
a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).
Sierra plans to conduct an open-label, multicenter Phase 1b/2 dose-ranging study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SRA737 in combination with niraparib in patients with mCRPC.
AbbVie, a global research and development based biopharmaceutical company, today announced positive top-line results from the Phase 2b randomized, placebo-controlled, dose-ranging study of upadacitinib (ABT-494), an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis not adequately controlled by topical treatments, or for whom topical treatments were not medically advisable.